rosiglitazone has been researched along with 17-alpha-hydroxyprogesterone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morin-Papunen, LC; Rautio, K; Ruokonen, A; Tapanainen, JS | 1 |
| Bahtiyar, G; Sacerdote, AS; Weiss, K | 1 |
1 trial(s) available for rosiglitazone and 17-alpha-hydroxyprogesterone
| Article | Year |
|---|---|
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Area Under Curve; Dehydroepiandrosterone; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Overweight; Placebos; Polycystic Ovary Syndrome; Rosiglitazone; Sex Hormone-Binding Globulin; Thiazolidinediones | 2006 |
1 other study(ies) available for rosiglitazone and 17-alpha-hydroxyprogesterone
| Article | Year |
|---|---|
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adult; Aged; Antipsychotic Agents; Cortodoxone; Dehydroepiandrosterone; Endocrine Disruptors; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Male; Metformin; Middle Aged; Radioimmunoassay; Rosiglitazone; Testosterone; Thiazolidinediones; Valproic Acid | 2007 |